Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.
作者信息
Bhatt Ankeet S, Vaduganathan Muthiah, Patel Ravi B, Fonarow Gregg C, Subacius Haris P, Konstam Marvin A, Zannad Faiez, Butler Javed, Greene Stephen J
机构信息
Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA.
Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
出版信息
Eur J Heart Fail. 2020 Jan;22(1):164-167. doi: 10.1002/ejhf.1651. Epub 2019 Dec 3.
Abstract
摘要
相似文献
1
Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.射血分数降低的心力衰竭住院患者出院后的血液稀释、充血及临床结局：EVEREST试验结果
Eur J Heart Fail. 2020 Jan;22(1):164-167. doi: 10.1002/ejhf.1651. Epub 2019 Dec 3.
2
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.心力衰竭住院患者住院期间呼吸困难状况的变化及出院后与健康相关的生活质量：来自EVEREST试验的结果。
Circ Heart Fail. 2016 May;9(5). doi: 10.1161/CIRCHEARTFAILURE.115.002458.
3
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.射血分数降低的心力衰竭住院患者的血液浓缩、肾功能和出院后结局：来自 EVEREST 试验的见解。
Eur J Heart Fail. 2013 Dec;15(12):1401-11. doi: 10.1093/eurjhf/hft110. Epub 2013 Jul 11.
4
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).评估血管加压素拮抗剂在心力衰竭中的疗效的多中心、随机、双盲、安慰剂对照研究的原理与设计：托伐普坦结局研究（EVEREST）
J Card Fail. 2005 May;11(4):260-9. doi: 10.1016/j.cardfail.2005.03.009.
5
Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).性别并不影响射血分数降低的心力衰竭恶化住院患者的出院后结局（来自托伐普坦治疗心力衰竭结局试验：血管加压素拮抗剂的疗效[EVEREST]研究）。
Am J Cardiol. 2012 Dec 15;110(12):1803-8. doi: 10.1016/j.amjcard.2012.08.016. Epub 2012 Sep 19.
6
Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.基于指南的心衰住院后治疗的真实世界分析。
J Am Heart Assoc. 2020 Aug 18;9(16):e015042. doi: 10.1161/JAHA.119.015042. Epub 2020 Aug 4.
7
Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).射血分数降低的心力衰竭病情恶化患者住院期间血清钾水平的变化（来自EVEREST试验）
Am J Cardiol. 2015 Mar 15;115(6):790-6. doi: 10.1016/j.amjcard.2014.12.045. Epub 2015 Jan 6.
8
Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.心力衰竭住院后使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂进行出院治疗与更好的预后相关，而与左心室射血分数无关。
Intern Med J. 2019 Dec;49(12):1505-1513. doi: 10.1111/imj.14289.
9
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.在 EVEREST 试验安慰剂组因心力衰竭恶化住院和出院后不久的患者住院期间肾功能的变化。
Eur Heart J. 2011 Oct;32(20):2563-72. doi: 10.1093/eurheartj/ehr238. Epub 2011 Jul 23.
10
The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.窦性节律、射血分数降低的心力衰竭住院患者心率的预后意义：EVEREST（血管加压素拮抗剂治疗心力衰竭的疗效：托伐普坦的结局研究）试验的观察结果。
JACC Heart Fail. 2013 Dec;1(6):488-96. doi: 10.1016/j.jchf.2013.08.005. Epub 2013 Dec 2.
引用本文的文献
1
The role of vitamin D in cardiovascular disease and COVID-19.维生素 D 在心血管疾病和 COVID-19 中的作用。
Rev Endocr Metab Disord. 2022 Apr;23(2):293-297. doi: 10.1007/s11154-021-09674-w. Epub 2022 Mar 2.
本文引用的文献
1
Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial.以患者为中心的过渡期护理服务对心力衰竭住院患者临床结局的影响：PACT-HF 随机临床试验。
JAMA. 2019 Feb 26;321(8):753-761. doi: 10.1001/jama.2019.0710.
2
The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.心力衰竭伴充血时利尿剂的应用——欧洲心脏病学会心力衰竭协会立场声明。
Eur J Heart Fail. 2019 Feb;21(2):137-155. doi: 10.1002/ejhf.1369. Epub 2019 Jan 1.
3
Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function.急性心力衰竭治疗期间血液浓缩对死亡率的影响及其与肾功能恶化的关系。
Eur J Heart Fail. 2017 Feb;19(2):226-236. doi: 10.1002/ejhf.667. Epub 2016 Oct 19.
4
The vulnerable phase after hospitalization for heart failure.心力衰竭住院后的脆弱期。
Nat Rev Cardiol. 2015 Apr;12(4):220-9. doi: 10.1038/nrcardio.2015.14. Epub 2015 Feb 10.
5
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.射血分数降低的心力衰竭住院患者的血液浓缩、肾功能和出院后结局：来自 EVEREST 试验的见解。
Eur J Heart Fail. 2013 Dec;15(12):1401-11. doi: 10.1093/eurjhf/hft110. Epub 2013 Jul 11.
6
Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival.积极利尿治疗失代偿性心力衰竭对肾功能和生存率的潜在影响。
Circulation. 2010 Jul 20;122(3):265-72. doi: 10.1161/CIRCULATIONAHA.109.933275. Epub 2010 Jul 6.
7
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine.评估和分级急性心力衰竭中的充血：欧洲心脏病学会心力衰竭协会急性心力衰竭委员会的科学声明，并得到欧洲重症监护医学学会的认可。
Eur J Heart Fail. 2010 May;12(5):423-33. doi: 10.1093/eurjhf/hfq045. Epub 2010 Mar 30.
8
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.口服托伐普坦对因心力衰竭加重而住院患者的影响：EVEREST结局试验
JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25.
9
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).评估血管加压素拮抗剂在心力衰竭中的疗效的多中心、随机、双盲、安慰剂对照研究的原理与设计：托伐普坦结局研究（EVEREST）
J Card Fail. 2005 May;11(4):260-9. doi: 10.1016/j.cardfail.2005.03.009.
Zotero 插件